secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001104659-24-011951
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune reports Q3 FY2024 net loss $51.1M; cash $466.4M; RP1 BLA plan for 2H 2024
--------------------------------------------------------------------------------

- Net loss of $51.1M for Q3 FY2024, up from $39.7M in prior year; R&D expenses $42.8M vs $30.3M.
- Cash, equivalents & short-term investments $466.4M as of Dec 31, 2023; cash runway extended into 2H 2026.
- BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024; Phase 3 confirmatory trial to start 2H 2024.
- RP2 data in uveal melanoma positive; planning for potential registrational trial in advanced uveal melanoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924011951/0001104659-24-011951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924011951/tm245513d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-011951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer